Moderna COVID Vaccine Still Has 'Best-In-Class Potential,' Says Barclays By: TalkMarkets August 06, 2020 at 09:30 AM EDT Barclays analyst Gena Wang raised the firm's price target on Moderna to $84 from $68 and keeps an Overweight rating on the shares. Read More >> Related Stocks: Moderna Inc Novavax Inc